Personalized treatment for T-cell lymphoma after first complete remission
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a specific type of peripheral T-cell lymphoma (PTCL-NOS, ALK-negative ALCL, or FTCL/PTCL-TFH).
- You completed your first standard chemotherapy (like CHOP) and achieved a complete remission.
- You are in good physical condition (able to do daily activities) and have adequate liver, kidney, and heart function.
- You do not have active infections (including hepatitis B or C, HIV, tuberculosis) or certain heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
This trial tests a combination of four chemotherapy drugs for people with a type of lymphoma called peripheral T-cell lymphoma who have not had treatment before. The goal is to see if this combination can help control the cancer.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.